• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Merck & Co (NY: MRK )

    127.51 -0.75 (-0.58%)
    Official Closing Price Updated: 7:00 PM EDT, May 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 6,221,953
    Open 128.01
    Bid (Size) 120.00 (4)
    Ask (Size) 134.68 (1)
    Prev. Close 128.26
    Today's Range 127.18 - 128.48
    52wk Range 99.14 - 133.10
    Shares Outstanding 2,531,374,696
    Dividend Yield 2.29%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Serum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo Therapy
    Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to expand BCG supply. FDA-approved Anktiva plus BCG for bladder cancer. 
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga

    Performance

    YTD
    +12.60%
    +12.60%
    1 Month
    -1.84%
    -1.84%
    3 Month
    +0.87%
    +0.87%
    6 Month
    +23.34%
    +23.34%
    1 Year
    +8.64%
    +8.64%

    More News

    Read More
    Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
    From Merck & Co., Inc.
    Via Business Wire
    Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Understanding Merck & Co's Position In Pharmaceuticals Industry Compared To Competitors
    Via Benzinga
    Looking Into Merck & Co's Recent Short Interest
    Via Benzinga
    Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
    From Merck & Co., Inc.
    Via Business Wire
    Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
    Via Talk Markets
    Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
    Via Investor's Business Daily
    3 Under-The-Radar Stocks With Positive Potential
    Via Talk Markets
    Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Merck (MRK) Q1 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
    Via Benzinga
    S&P 500 Down Over 1%; Merck Increases 2024 Outlook
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Meta Falls 15% On Great Earnings, Tesla Rises 12% On Ugly Earnings – Here Is The Real Reason
    Via Benzinga
    Merck Rides Keytruda To Another Beat-And-Raise, But Diabetes Headwinds Persist
    Via Investor's Business Daily
    Merck Announces First-Quarter 2024 Financial Results
    From Merck & Co., Inc.
    Via Business Wire
    US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
    Via Benzinga
    Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
    Via Benzinga
    Investor Alert: Prepare for the Market Crash With These 3 Stocks
    Via InvestorPlace
    3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
    Via InvestorPlace
    Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.